These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 33245444)
41. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient]. Sun Y; Li L; Zhou TY; Lu W Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196 [TBL] [Abstract][Full Text] [Related]
42. Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT). Christensen HD; Sheta HM; Morillon MB; Hansen IM Am J Case Rep; 2016 Jul; 17():494-8. PubMed ID: 27418121 [TBL] [Abstract][Full Text] [Related]
44. Evaluating appropriate use of prophylactic colchicine for gout flare prevention. George M; Pullman-Mooar S; Hussain F; Schumacher HR Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081 [TBL] [Abstract][Full Text] [Related]
45. Advances in pharmacotherapy for the treatment of gout. Robinson PC; Dalbeth N Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991 [TBL] [Abstract][Full Text] [Related]
46. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout. Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906 [TBL] [Abstract][Full Text] [Related]
47. Up-titration of allopurinol in patients with gout. Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM; Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169 [TBL] [Abstract][Full Text] [Related]
48. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Zhang T; Pope JE Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501 [TBL] [Abstract][Full Text] [Related]
49. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549 [TBL] [Abstract][Full Text] [Related]
50. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Singh JA; Akhras KS; Shiozawa A Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969 [TBL] [Abstract][Full Text] [Related]
51. Major unanswered questions in the clinical gout field. Stamp LK Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541 [TBL] [Abstract][Full Text] [Related]
52. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847 [TBL] [Abstract][Full Text] [Related]
54. Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. Vargas-Santos AB; Castelar-Pinheiro Gda R; Coutinho ES; Schumacher HR; Singh JA; Schlesinger N PLoS One; 2015; 10(8):e0135805. PubMed ID: 26274585 [TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore. Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360 [No Abstract] [Full Text] [Related]
56. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Kim SC; Schmidt BM; Franklin JM; Liu J; Solomon DH; Schneeweiss S Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2008-14. PubMed ID: 23861232 [TBL] [Abstract][Full Text] [Related]
57. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007 [TBL] [Abstract][Full Text] [Related]
58. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584 [TBL] [Abstract][Full Text] [Related]
59. A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia. Terrill M; Riordan J Int J Rheum Dis; 2018 Feb; 21(2):517-522. PubMed ID: 28544467 [TBL] [Abstract][Full Text] [Related]